Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SoftOx Solutions AS ( (DE:6FV) ) just unveiled an update.
SoftOx Solutions AS has successfully manufactured its first GMP batch of the SoftOx Inhalation Solution Drug Substance, marking a crucial advancement in its clinical and technological development. This achievement underscores SoftOx’s capability to transition from research to GMP-compliant clinical manufacturing, enhancing its role in healthcare innovation and defense preparedness. The development strengthens SoftOx’s position in the clinical pipeline, demonstrating operational capability and regulatory compliance, while increasing investor value as the company approaches trial execution and commercialization.
More about SoftOx Solutions AS
SoftOx Solutions AS is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company specializes in developing pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi, leveraging extensive research and development collaborations with leading Nordic research institutes.
YTD Price Performance: 400%
Average Trading Volume: 14,159,403
Current Market Cap: NOK163.6M
For an in-depth examination of 6FV stock, go to TipRanks’ Overview page.